Ongoing and future large, controlled studies including central consensus review, AFP at diagnosis for every patient, and INI1 immunohistochemistry or SMARCB1 genetic testing for suspected rhabdoid tumor cases would be required to confirm these findings. This evidence concerns the gene SMARCB1 and rhabdoid tumor.